CA2437168A1 - Retinoid hepatitis therapy - Google Patents

Retinoid hepatitis therapy Download PDF

Info

Publication number
CA2437168A1
CA2437168A1 CA002437168A CA2437168A CA2437168A1 CA 2437168 A1 CA2437168 A1 CA 2437168A1 CA 002437168 A CA002437168 A CA 002437168A CA 2437168 A CA2437168 A CA 2437168A CA 2437168 A1 CA2437168 A1 CA 2437168A1
Authority
CA
Canada
Prior art keywords
hepatitis
therapeutically effective
retinoic acid
effective amount
trans retinoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002437168A
Other languages
English (en)
French (fr)
Inventor
Anthony H. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aronex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2437168A1 publication Critical patent/CA2437168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002437168A 2001-02-02 2002-01-31 Retinoid hepatitis therapy Abandoned CA2437168A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26597701P 2001-02-02 2001-02-02
US60/265,977 2001-02-02
PCT/US2002/002996 WO2002066022A1 (en) 2001-02-02 2002-01-31 Retinoid hepatitis therapy

Publications (1)

Publication Number Publication Date
CA2437168A1 true CA2437168A1 (en) 2002-08-29

Family

ID=23012660

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002437168A Abandoned CA2437168A1 (en) 2001-02-02 2002-01-31 Retinoid hepatitis therapy

Country Status (4)

Country Link
EP (1) EP1363611A4 (de)
JP (1) JP2004522770A (de)
CA (1) CA2437168A1 (de)
WO (1) WO2002066022A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514094A (ja) * 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Ｃ型肝炎ウイルス感染に対して有用な製剤
DE10305138A1 (de) * 2003-02-07 2004-08-26 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2018054891A1 (en) * 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5166319A (en) * 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
GB0020351D0 (en) * 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
EP1363611A4 (de) 2004-08-11
EP1363611A1 (de) 2003-11-26
JP2004522770A (ja) 2004-07-29
WO2002066022A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
AU2023204000A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
WO2006092741A2 (en) Treatment of inflammatory disorders with praziquantel
WO2010128889A1 (ru) Фармацевтическая композиция, включающая арбидол в составе фосфолипидных наночастиц
BRPI0618529A2 (pt) meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro
WO2006105155A2 (en) Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms
ZA200502452B (en) Remedy
TWI302459B (de)
US20230263748A1 (en) Application of benflumetol and derivatives thereof in treatment of coronavirus infection
CA2437168A1 (en) Retinoid hepatitis therapy
US20040127566A1 (en) Retinoid hepatitis therapy
JPH05331061A (ja) アポトーシス誘起剤
JPS63500944A (ja) ウイルスの不活化
WO1989001764A1 (en) Acquired immune deficiency syndrome/acquired immune deficiency syndrome related complex---palliative for
JP2007506645A (ja) 抗腫瘍および抗転移のための製剤の製造におけるｎ−アセチル−ｄ−グルコサミンの使用
WO2006053487A1 (fr) Utilisation de derives vegetaux de l’anthraquinone et de polysaccharides vegetaux destines au traitement du virus de l’immunodeficience humaine (vih)
US6468991B1 (en) Method of treating rhinoviral infections
DE3780157T2 (de) Verwendung von 4-butyl-1,2-diphenyl-pyrazolidin-3,5-dion als antivirales arzneimittel gegen aids.
CN1504191A (zh) 葫芦素脂质体组方及其制剂
US20100016244A1 (en) D-glucopyranose 1-[3,5-bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and use thereof
CN107281199A (zh) N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物
Kocięcka et al. The effect of Thymus Factor X (TFX Polfa) on the clinical course of human trichinellosis
CN1679914A (zh) 还原型谷胱甘肽和依布硒啉的组合药物
RU2104023C1 (ru) Лекарственное средство для лечения ретровирусных инфекций
CN117180448A (zh) 载siRNA/NTCP-Ab氟碳脂质纳米粒及其应用
WO2023277730A1 (ru) Лекарственное средство для профилактики заражения sars-cov-2

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060131